23 Results for "

dotam-nhs-ester

" in MedChemExpress (MCE) Product Catalog:
Products (23)

23 Results for "dotam-nhs-ester" in MCE Product Catalog:

4
CCZ01048 TFA
CCZ01048 TFA
0 Images
4 Cited Publications
Referencia número: HY-P2336A
Target:  

Melanocortin Receptor

Áreas de investigación:  

Cancer

CCZ01048 TFA, a α-MSH analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a Ki of 0.31 nM. CCZ01048 TFA shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 TFA is a promising candidate for PET imaging of malignant melanoma .
loading...
    loading...
View All Sizes
Glutathione ethyl ester
Glutathione ethyl ester
0 Images
Referencia número: HY-134124
No. CAS: 92614-59-0
Pureza:  95.8%
Target:  

Reactive Oxygen Species (ROS)

Áreas de investigación:  

Metabolic Disease

Glutathione ethyl ester is a cell-permeable GSH donor and provides an efficient supply of GSH to the oocyte. Glutathione ethyl ester shows positive effect on the in vitro production of embryos by enhancement of the antioxidative defense .
loading...
    loading...
View All Sizes
DOTAMTATE
DOTAMTATE
0 Images
Referencia número: HY-P10920
No. CAS: 2415661-92-4
Target:  

Drug Derivative

Áreas de investigación:  

Cancer

DOTAMTATE is a somatostatin analogue. DOTAMTATE marked 212Pb is promising for research of somatostatin receptor positive neuroendocrine tumors .
loading...
    loading...
View All Sizes
DOTA-Pep-1L TFA
DOTA-Pep-1L TFA
0 Images
Referencia número: HY-P11287A
Target:  

Interleukin Related Radionuclide-Drug Conjugates (RDCs)

Áreas de investigación:  

Cancer

DOTA-Pep-1L TFA is a polypeptide formed by the conjugation of DOTA and Pep-1L. DOTA-Pep-1L TFA specifically binds to IL13RA2 and can be used for the synthesis of targeted polypeptides. DOTA-Pep-1L TFA yields the isotopically labeled product [ 225Ac]DOTA-Pep-1L, which exerts α-radiation killing effects on orthotopic glioma cells and extends the median survival time of mice bearing orthotopic glioma models after stereotactic injection. DOTA-Pep-1L TFA can be used for PET imaging, tumor targeting and glioma research .
loading...
    loading...
View All Sizes
3BP-3940
3BP-3940
0 Images
Referencia número: HY-P10131
No. CAS: 2803421-14-7
Target:  

Radionuclide-Drug Conjugates (RDCs) FAP

Áreas de investigación:  

Cancer

3BP-3940 is a highly potent and selective peptide inhibitor of FAP that targets cancer-associated fibroblasts (CAFs) in the tumor microenvironment. 3BP-3940 can be labeled with radionuclides (such as Ga-68) for precise tumor imaging or Lu-177 for the development of targeted anticancer technologies. 3BP-3940 accumulates in tumor lesions and can be used to diagnose and inhibit various solid cancers and CAFs-related diseases .
loading...
    loading...
View All Sizes
DOTA-NOC
DOTA-NOC
0 Images
Referencia número: HY-P2112
No. CAS: 619300-53-7
Synonyms: DOTA-Nal3-octreotide
Target:  

Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor

Áreas de investigación:  

Others

DOTA-NOC (DOTA-Nal3-octreotide) is a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5. DOTA-NOC can be used for labeling with various radiometals, and development of radiopeptide imaging . DOTA-NOC can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
loading...
    loading...
View All Sizes
DOTA-Octreotide TFA
DOTA-Octreotide TFA
0 Images
Referencia número: HY-P10273A
Target:  

Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents

Áreas de investigación:  

Cancer

DOTA-Octreotide TFA is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide TFA is used for research of cancer through combination with radioactive elements. DOTA-Octreotide TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
loading...
    loading...
View All Sizes
DOTA-Pep-1L
DOTA-Pep-1L
0 Images
Referencia número: HY-P11287
Target:  

Interleukin Related Radionuclide-Drug Conjugates (RDCs)

Áreas de investigación:  

Cancer

DOTA-Pep-1L is a polypeptide formed by the conjugation of DOTA and Pep-1L. DOTA-Pep-1L specifically binds to IL13RA2 and can be used for the synthesis of targeted polypeptides. DOTA-Pep-1L yields the isotopically labeled product [ 225Ac]DOTA-Pep-1L, which exerts α-radiation killing effects on orthotopic glioma cells and extends the median survival time of mice bearing orthotopic glioma models after stereotactic injection. DOTA-Pep-1L can be used for PET imaging, tumor targeting and glioma research .
loading...
    loading...
View All Sizes
DOTA-TMVP1446
DOTA-TMVP1446
0 Images
Referencia número: HY-P11026
Synonyms: DOTA-PEG4-TMVP1446
Target:  

VEGFR

Áreas de investigación:  

Cancer

DOTA-TMVP1446 is a VEGFR-3 targeting peptide. DOTA-TMVP1446 labeled with 68Ga accurately detectes the status of lymph node metastasis, even in micrometastatic tumors, in the B16-F10 tumor mice model. DOTA-TMVP1446 can be used as a radiotracer for cancer-metastatic sentinel lymph nodes (m-SLN) imaging .
loading...
    loading...
View All Sizes
DOTA Conjugated JM#21 derivative 7
DOTA Conjugated JM#21 derivative 7
0 Images
Referencia número: HY-P10444
No. CAS: 3033865-40-3
Target:  

Radionuclide-Drug Conjugates (RDCs) CXCR

Áreas de investigación:  

Cancer

DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney . DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
loading...
    loading...
View All Sizes
DOTA-CXCR4-L
DOTA-CXCR4-L
0 Images
Referencia número: HY-P5297
Target:  

Radionuclide-Drug Conjugates (RDCs) CXCR

Áreas de investigación:  

Cancer

DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer. NODAGA-LM3 can be labeled with [68Ga]/[177Lu] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
loading...
    loading...
View All Sizes
DOTA-ubiquicidin (29–41)
DOTA-ubiquicidin (29–41)
0 Images
Referencia número: HY-P10307
Target:  

Radionuclide-Drug Conjugates (RDCs) Bacterial

Áreas de investigación:  

Infection

DOTA-ubiquicidin (29-41), an antimicrobial peptide fragment derivative, can be used for synthesis of [ 68Ga]Ga-DOTA-Ubiquicidin29-41 and then used for imaging of infectious processes using PET/CT . DOTA-ubiquicidin (29–41) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
loading...
    loading...
View All Sizes
(R)-Zadavotide guraxetan
(R)-Zadavotide guraxetan
0 Images
Referencia número: HY-P10951
No. CAS: 2647371-60-4
Synonyms: (R)-PSMA I&T; (R)-PNT-2002
Target:  

PSMA

Áreas de investigación:  

Cancer

Zadavotide guraxetan (PSMA I&T; PNT-2002) is a prostate-specific membrane antigen (PSMA) inhibitor. Zadavotide guraxetan has antitumor activity and can be used in prostate cancer-targeted research .
loading...
    loading...
View All Sizes
Cholecystokinin-J
Cholecystokinin-J
0 Images
Referencia número: HY-P2424
No. CAS: 144396-38-3
Synonyms: CCK-J
Target:  

Calcium Channel

Áreas de investigación:  

Others

Cholecystokinin-J (CCK-J), a cholecystokinin, stimulates Ca 2+ release .
loading...
    loading...
View All Sizes
DOTA-Octreotide
DOTA-Octreotide
0 Images
Referencia número: HY-P10273
No. CAS: 209277-09-8
Target:  

Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents

Áreas de investigación:  

Cancer

DOTA-Octreotide is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide is used for research of cancer, through combination with radioactive elements. DOTA-Octreotide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
loading...
    loading...
View All Sizes
DOTA-WC8
DOTA-WC8
0 Images
Referencia número: HY-P11613
Target:  

EGFR

Áreas de investigación:  

Cancer

DOTA-WC8 is a HER2-targeting peptide probe with a KD of 61.20 nM. 68Ga-labeled DOTA-WC8 serves as a PET imaging agent for the specific identification of HER2-positive breast cancer. DOTA-WC8 is applicable to breast cancer-related research .
loading...
    loading...
View All Sizes
DOTA-ECL1i
DOTA-ECL1i
0 Images
Referencia número: HY-P11553B
No. CAS: 2850189-48-7
Target:  

Radionuclide-Drug Conjugates (RDCs) CCR

Áreas de investigación:  

Cardiovascular Disease Inflammation/Immunology Cancer

DOTA-ECL1i is a conjugate of the CCR2 inhibitor ECL1i (HY-P11553) and DOTA. When radiolabeled with 68Ga, DOTA-ECL1i serves as a PET tracer that targets CCR2 expression. DOTA-ECL1i can be used in research related to pulmonary fibrosis, cardiac injury, abdominal aortic aneurysm inflammation, atherosclerosis, head and neck cancer, and pancreatic cancer .
loading...
    loading...
View All Sizes
SU015
SU015
0 Images
Referencia número: HY-P3335
No. CAS: 250612-06-7
Synonyms: DOTA-RGDfK dimer
Target:  

Integrin Radionuclide-Drug Conjugates (RDCs)

Áreas de investigación:  

Cardiovascular Disease Cancer

SU015 (DOTA-RGDfK dimer) is a Integrin αvβ5 and αvβ3 antagonist. SU015 exhibits comparable affinity for αvβ5 and αvβ3, with relatively higher potency and specificity compared to other integrins. SU015 inhibits αvβ3-mediated cell adhesion to fibrinogen, αvβ3-mediated adhesion of activated platelets to osteopontin, and αvβ5-mediated cell adhesion to vitronectin. SU015 shows potent inhibitory effects on FGF2-induced angiogenesis in the CAM model. SU015 carries a linker arm available for radioisotope conjugation, and acts as a target-specific radioreagent when labeled with 90Y (i.e., RP697) or 177Lu (i.e., RP688). SU015 can be used in studies related to tumor metastasis and tumors .
loading...
    loading...
View All Sizes
DOTA-cTMTP1
DOTA-cTMTP1
0 Images
Referencia número: HY-P11816
Target:  

Radionuclide-Drug Conjugates (RDCs)

Áreas de investigación:  

Cancer

DOTA-cTMTP1 is a cyclic tumor-homing peptide precursor molecule. DOTA-cTMTP1 selectively binds to XPNPEP2 on highly metastatic tumor cells, accumulates and retains in hepatocellular carcinoma tumors, and maintains a high tumor-to-liver contrast over time in small animal models. After radiolabeling with 68Ga, DOTA-cTMTP1 forms a PET probe for positron emission tomography (PET) imaging of hepatocellular carcinoma (HCC).
loading...
    loading...
View All Sizes
DOTA-SMIC-1014
DOTA-SMIC-1014
0 Images
Referencia número: HY-P11864
Target:  

c-Met/HGFR Radionuclide-Drug Conjugates (RDCs)

Áreas de investigación:  

Cancer

DOTA-SMIC-1014 is a DOTA chelator-conjugated precursor of the c-Met-targeting peptide SMIC-1014 (HY-P11863). DOTA-SMIC-1014 binds to the extracellular domain of c-Met (Kd = 42.83 nM). After radiolabeling to [ 68Ga]Ga-SMIC-1014, DOTA-SMIC-1014 acts as a positron emission tomography (PET) probe that achieves specific tumor uptake in xenografts and functions as a diagnostic probe targeting c-Met. SMIC-1014 can be used in research related to colon cancer, hepatocellular carcinoma, and prostate cancer .
loading...
    loading...
View All Sizes
Assay Types